Veloce BioPharma LLC reports today that their Halodine(R) Antiseptics have 
demonstrated rapid viricidal efficacy against SARS-CoV-2, the virus that causes 
COVID-19. Halodine(R) is a proprietary povidone-iodine antiseptic developed in 
partnership with leading clinicians for repeated nasal and oral administration. 
In experiments conducted with The Institute for Antiviral Research at Utah 
State University, a BSL3+ laboratory, the proprietary Halodine(R) nasal and 
oral antiseptic preparations were proven to rapidly inactivate SARS-CoV-2. It 
has been proven to be effective against SARS-CoV-2 even at dilutions as low as 
1/20 of the commercially available solutions.

Logo - https://mma.prnewswire.com/media/753707/Veloce_BioPharma_Logo.jpg

Logo - https://mma.prnewswire.com/media/1168054/Halodine_Logo.jpg 

"This study shows that a non-toxic nasal and oral solution is also effective 
against SARS-CoV-2. This is the first iodine-based antiseptic that has ever 
been shown to have activity against the virus that causes COVID-19," said lead 
author Jesse Pelletier MD FACS, of Ocean Ophthalmology Group (Miami, FL). "Now 
that we finally have proven efficacy against SARS-CoV-2 for povidone-iodine 
solutions that are safe for mucosa, we can incorporate them in to our COVID-19 
transmission reduction efforts." Dr. Pelletier is leading efforts to design 
safe return-to-work protocols for ophthalmology outpatient clinics and 
ambulatory surgery centers. 

Halodine(R) and COVID-19
The Halodine(R) ( 
https://c212.net/c/link/?t=0&l=en&o=2803797-1&h=860958419&u=http%3A%2F%2Fwww.halodine.com%2F&a=Halodine 
) family of antiseptics are based on a polymer-enriched povidone-iodine which 
is non-toxic to mucosal surfaces. They are specially developed for the safe, 
repeated use in the nose and mouth. The high viral loads in the nose and mouth 
create a transmission risk, especially in health care settings. Nasal and 
respiratory aerosols and droplets have been shown to be a main source of 
COVID-19 transmission. 

Viral aerosols and droplets can remain infectious for up to three hours. Masks 
can help protect against infection, but with nasal and oral antiseptics that 
are proven to be effective against the virus, aerosol transmission may be able 
to be reduced. Masks alone cannot eliminate the virus. Dr. Pelletier 
emphasized, "Nasal antisepsis and oral rinses are an important part of 
transmission reduction with masks, just like handwashing is important with 
gloves." 

"There is much that is still being learned about this novel coronavirus and its 
behavior," said Samuel Barone MD, Chief Medical Officer of Veloce BioPharma. 
"We have been working on iodophor-based antiviral therapies in dermatology and 
ophthalmology for a few years and the Halodine(R) Antiseptic program grew out 
of that experience. We are extremely encouraged by these results that for the 
first time demonstrate efficacy against the virus that causes COVID-19."

About Veloce BioPharma LLC
Veloce BioPharma LLC is a clinical stage biopharmaceutical company focused on 
development of novel antiviral therapies in dermatology and ophthalmology. 
Veloce BioPharma was founded and is led by practicing MDs. 

Contact : contact@halodine.com, 
sbarone@velocebiopharma.com 

SOURCE: Veloce BioPharma LLC